Bank Of New York Mellon Corp Dyne Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$10.88 - $15.0 $1.38 Million - $1.9 Million	126,863 New	126,863 $1.46 Billion
Q4 2022 Feb 14, 2023	BUY	$9.37 - $13.8 $1.19 Million - $1.76 Million	127,295 New	127,295 $1.48 Million
Q3 2022 Nov 14, 2022	BUY	$7.2 - $15.17 $72,468 - $152,686	10,065 Added 9.19%	119,566 $1.52 Million
Q2 2022 Aug 15, 2022	SELL	$4.36 - $10.5 $11,274 - $27,153	-2,586 Reduced 2.31%	109,501 $752,000
Q1 2022 May 11, 2022	SELL	$6.52 - $12.27 $25,167 - $47,362	-3,860 Reduced 3.33%	112,087 $1.08 Million
Q4 2021 Feb 11, 2022	SELL	$11.89 - $16.07 $3.44 Million - $4.65 Million	-289,315 Reduced 71.39%	115,947 $1.38 Million
Q3 2021 Nov 12, 2021	BUY	$15.6 - $21.46 $244,202 - $335,934	15,654 Added 4.02%	405,262 $6.58 Million
Q2 2021 Aug 11, 2021	BUY	$15.94 - $22.33 $2.43 Million - $3.4 Million	152,461 Added 64.29%	389,608 $8.2 Million
Q1 2021 May 13, 2021	BUY	$14.0 - $29.3 $1.22 Million - $2.55 Million	86,914 Added 57.85%	237,147 $3.68 Million
Q4 2020 Feb 09, 2021	BUY	$16.81 - $23.94 $806,980 - $1.15 Million	48,006 Added 46.96%	150,233 $3.15 Million
Q3 2020 Nov 12, 2020	BUY	$20.0 - $23.9 $2.04 Million - $2.44 Million	102,227 New	102,227 $2.06 Million

209

102M

234K

238K

Ticker DYN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,765,400
Market Cap $701M
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.